Test Summary

This test is intended for the qualitative detection of Zika virus in serum from individuals who meet the Centers for Disease Control and Prevention (CDC) clinical and epidemiological criteria for Zika virus testing. Zika viruses are primarily transmitted by Aedes aegypti and Aedes albopictus mosquitos [1].

Most individuals with Zika infections are asymptomatic. Individuals with symptomatic infections may experience fever, rash, and muscle/joint pain [2].

Per the 2019 CDC guidelines, testing is recommended only for symptomatic pregnant women with a history of living in or traveling to a geographic area at risk for Zika. For current testing guidelines, see https://www.cdc.gov/zika/hc-providers/testing-guidance.html
⁠⁠⁠⁠⁠⁠⁠
For individuals meeting the CDC criteria, concurrent testing of serum and urine is recommended as soon as possible after symptom onset.

Zika infection shares clinical and epidemiological features with other arbovirus infections such as Dengue and Chikungunya. For CDC guidelines on testing concurrently for Zika and Dengue, see https://www.cdc.gov/dengue/healthcare-providers/testing/testing-guidance.html

1. Subcommittee on Laboratory Practices, ASM, and Public Relations Committee, Pan American Society for Clinical Virology (PASCV). Zika virus: An Update on the Disease and Guidance for Laboratory Testing. September 2022. Accessed May 9, 2023. https://asm.org/Guideline/Zika-virus-An-update-on-the-disease-and-guidance-f
2. Sharp TM, et al. MMWR Recomm Rep. 2019 Jun 14;68(1):1-10.

Aliases

Specimen Collection

Special Instructions

Preferred Specimen

Minimum Volume

Instructions

Patient Preparation

Storage

Transport Temperature

Specimen Stability

Limitations

Other Acceptable Specimens

Unacceptable Specimens

Order Code

EPIC (Premier) Code

Includes

CPT Code

Billing Code

CPT Statement

Methodology

FDA Status

Physician Attestation of Informed Consent

Testing Laboratory

Reference Range

Setup Schedule / Expected Turnaround Time